

# Rob Veerhuis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7597568/publications.pdf>

Version: 2024-02-01

113  
papers

11,625  
citations

43973

48  
h-index

30848

102  
g-index

134  
all docs

134  
docs citations

134  
times ranked

14003  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2022, 19, 50.	3.1	26
2	The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 32.	2.5	19
3	α-synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia. <i>Glia</i> , 2021, 69, 1413-1428.	2.5	58
4	The pattern of inflammatory markers during electroconvulsive therapy in older depressed patients. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 770-777.	1.3	4
5	Inflammation and Cognitive Functioning in Depressed Older Adults Treated With Electroconvulsive Therapy. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	11
6	APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	3.0	28
7	Impaired Innate Immunity Mechanisms in the Brain of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1126.	1.8	13
8	Inflammation in older subjects with early- and late-onset depression in the NESDO study: a cross-sectional and longitudinal case-only design. <i>Psychoneuroendocrinology</i> , 2019, 99, 20-27.	1.3	19
9	Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study. <i>Journal of Affective Disorders</i> , 2019, 256, 509-516.	2.0	20
10	S100 calcium-binding protein B in older patients with depression treated with electroconvulsive therapy. <i>Psychoneuroendocrinology</i> , 2019, 110, 104414.	1.3	5
11	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019, 79, 101-109.	1.5	12
12	Aβ-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-Aβ single chain variable fragment in combination with an apoE mimetic peptide. <i>Molecular and Cellular Neurosciences</i> , 2018, 89, 49-59.	1.0	21
13	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 687-697.	1.2	60
14	CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. <i>Neurobiology of Aging</i> , 2017, 57, 186-194.	1.5	26
15	[P3ε161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL Aβ CLEARANCE?. <i>Alzheimer's and Dementia</i> , 2017, 13, P995.	0.4	0
16	Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides. <i>PLoS ONE</i> , 2017, 12, e0188191.	1.1	12
17	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
18	Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 35-43.	1.2	52

#	ARTICLE	IF	CITATIONS
19	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1103-1110.	1.2	55
20	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. <i>Frontiers in Neurology</i> , 2015, 6, 202.	1.1	24
21	Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue. <i>Journal of Neuroimmunology</i> , 2015, 278, 271-276.	1.1	48
22	Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A $\beta$ by insulin degrading enzyme (IDE) in Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 589, 47-51.	1.0	13
23	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. <i>Clinical Immunology</i> , 2015, 158, 92-99.	1.4	2
24	Quantification of clusterin in paired cerebrospinal fluid and plasma samples. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 557-567.	0.8	12
25	Apolipoproteins E and J interfere with amyloid- $\beta$ uptake by primary human astrocytes and microglia <i>in vitro</i> . <i>Glia</i> , 2014, 62, 493-503.	2.5	71
26	Complement Activation by Ceramide Transporter Proteins. <i>Journal of Immunology</i> , 2014, 192, 1154-1161.	0.4	21
27	ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. <i>Neurobiology of Aging</i> , 2014, 35, 565-575.	1.5	46
28	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1596-1604.	1.5	46
29	O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, P195-P196.		0
30	P3-031: AMYLOID-BETA DEGRADATION BY HUMAN ASTROCYTES IS IMPAIRED BY APOJ AND APOE. , 2014, 10, P638-P638.		1
31	P1-096: IRAK-4 KINASE INHIBITION REDUCES PRO-INFLAMMATORY CYTOKINE SECRETION BUT HAS NO EFFECT ON THE UPTAKE OF AMYLOID BETA BY HUMAN GLIAL CELLS. , 2014, 10, P337-P337.		0
32	NG2 cells, a new trail for Alzheimer's disease mechanisms?. <i>Acta Neuropathologica Communications</i> , 2013, 1, 7.	2.4	50
33	Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1079-1083.	1.1	26
34	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , 2013, 9, 276-283.	0.4	25
35	Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid $\beta$ -peptide. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 179-187.	1.4	18
36	Goodpasture Antigen-binding Protein/Ceramide Transporter Binds to Human Serum Amyloid P-Component and Is Present in Brain Amyloid Plaques. <i>Journal of Biological Chemistry</i> , 2012, 287, 14897-14911.	1.6	31

#	ARTICLE	IF	CITATIONS
37	2.131 CSF CLUSTERIN IS ASSOCIATED WITH COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BIOMARKERS IN PARKINSON'S DISEASE PATIENTS. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S109.	1.1	0
38	Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 15.	3.0	90
39	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012, 33, 1591-1598.	1.5	52
40	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.	1.5	55
41	The effect of amyloid associated proteins on the expression of genes involved in amyloid- $\beta^2$ clearance by adult human astrocytes. <i>Experimental Neurology</i> , 2012, 233, 373-379.	2.0	81
42	Soothing the Inflamed Brain: Effect of Non-Steroidal Anti-Inflammatory Drugs on Alzheimers Disease Pathology. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 57-67.	0.8	34
43	The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence. <i>Current Alzheimer Research</i> , 2011, 8, 142-150.	0.7	92
44	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1073-1079.	1.2	21
45	Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. <i>European Journal of Neurology</i> , 2011, 18, 865-871.	1.7	51
46	Complement in the brain. <i>Molecular Immunology</i> , 2011, 48, 1592-1603.	1.0	345
47	Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD. <i>Current Alzheimer Research</i> , 2011, 8, 34-58.	0.7	69
48	Small Heat Shock Proteins Induce a Cerebral Inflammatory Reaction. <i>Journal of Neuroscience</i> , 2011, 31, 11992-12000.	1.7	36
49	The Pre-Eclampsia Gene STOX1 Controls a Conserved Pathway in Placenta and Brain Upregulated in Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 673-679.	1.2	40
50	Biomarkers of inflammation and amyloid- $\beta^2$ phagocytosis in patients at risk of Alzheimer disease. <i>Experimental Gerontology</i> , 2010, 45, 57-63.	1.2	44
51	Apolipoprotein E protects cultured pericytes and astrocytes from D- $\beta$ 40-mediated cell death. <i>Brain Research</i> , 2010, 1315, 169-180.	1.1	45
52	Astrocytic $\beta$ 42 uptake is determined by $\beta$ aggregation state and the presence of amyloid-associated proteins. <i>Glia</i> , 2010, 58, 1235-1246.	2.5	139
53	Additional Value of CSF Amyloid- $\beta^2$ 40 Levels in the Differentiation between FTLD and Control Subjects. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 445-452.	1.2	39
54	Inflammatory markers in AD and MCI patients with different biomarker profiles—interpretation of serum and CSF levels. <i>Neurobiology of Aging</i> , 2010, 31, 1655.	1.5	0

#	ARTICLE	IF	CITATIONS
55	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 253-260.	1.2	75
56	CSF levels of PSA and PSA- $\beta$ -ACT complexes in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 477-483.	0.8	9
57	Quantification of amyloid-beta 40 in cerebrospinal fluid. <i>Journal of Immunological Methods</i> , 2009, 348, 57-66.	0.6	21
58	Binding and uptake of $A\beta_{1-42}$ by primary human astrocytes <i>in vitro</i> . <i>Glia</i> , 2009, 57, 978-988.	2.5	86
59	Small heat shock proteins associated with cerebral amyloid angiopathy of hereditary cerebral hemorrhage with amyloidosis (Dutch type) induce interleukin-6 secretion. <i>Neurobiology of Aging</i> , 2009, 30, 229-240.	1.5	39
60	Inflammatory markers in AD and MCI patients with different biomarker profiles. <i>Neurobiology of Aging</i> , 2009, 30, 1885-1889.	1.5	135
61	Preferential uptake of amyloid beta $1-42$ oligomers by primary human astrocytes <i>in vitro</i> : Influence of SAP and C1q. <i>Molecular Immunology</i> , 2009, 46, 2860.	1.0	0
62	Homogeneity of active demyelinating lesions in established multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 16-25.	2.8	309
63	Neuroinflammation in Early Stages of Alzheimer's Disease and Parkinson's Disease. , 2008, , 113-121.		0
64	C4b-binding protein in Alzheimer's disease: Binding to $A\beta_{1-42}$ and to dead cells. <i>Molecular Immunology</i> , 2008, 45, 3649-3660.	1.0	46
65	Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 522-527.	0.7	27
66	Neuroinflammation in Plaque and Vascular $\beta$ -Amyloid Disorders: Clinical and Therapeutic Implications. <i>Neurodegenerative Diseases</i> , 2008, 5, 190-193.	0.8	48
67	Increased $\beta$ -42 Production Sensitizes Neuroblastoma Cells for ER Stress Toxicity. <i>Current Alzheimer Research</i> , 2008, 5, 469-474.	0.7	36
68	Cyclooxygenase-1 and -2 in the Different Stages of Alzheimer's Disease Pathology. <i>Current Pharmaceutical Design</i> , 2008, 14, 1419-1427.	0.9	128
69	Minocycline does not affect amyloid $\beta$ phagocytosis by human microglial cells. <i>Neuroscience Letters</i> , 2007, 416, 87-91.	1.0	50
70	Lipoprotein Receptor-Related Protein-1 Mediates Amyloid- $\beta$ -Mediated Cell Death of Cerebrovascular Cells. <i>American Journal of Pathology</i> , 2007, 171, 1989-1999.	1.9	120
71	ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 956-958.	1.3	10
72	The Involvement of $A\beta$ in the Neuroinflammatory Response. , 2007, , 52-82.		1

#	ARTICLE	IF	CITATIONS
73	Amyloid $\beta$ peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. <i>Neurochemistry International</i> , 2006, 48, 663-672.	1.9	48
74	Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. <i>International Journal of Developmental Neuroscience</i> , 2006, 24, 157-165.	0.7	142
75	Interleukin-1 beta-induced expression of the prostaglandin E2-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. <i>Journal of Neurochemistry</i> , 2006, 96, 680-693.	2.1	31
76	The significance of neuroinflammation in understanding Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 1685-1695.	1.4	243
77	The unfolded protein response affects neuronal cell cycle protein expression: Implications for Alzheimer's disease pathogenesis. <i>Experimental Gerontology</i> , 2006, 41, 380-386.	1.2	51
78	Inhibitory effect of minocycline on amyloid $\beta$ fibril formation and human microglial activation. <i>Glia</i> , 2006, 53, 233-240.	2.5	75
79	Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 735-737.	0.9	30
80	DNA Polymerase-beta Is Expressed Early in Neurons of Alzheimer's Disease Brain and Is Loaded into DNA Replication Forks in Neurons Challenged with beta-Amyloid. <i>Journal of Neuroscience</i> , 2006, 26, 10949-10957.	1.7	76
81	The Pathology of Multiple Sclerosis Is Location-Dependent: No Significant Complement Activation Is Detected in Purely Cortical Lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 147-155.	0.9	165
82	The unfolded protein response is activated in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2005, 110, 165-172.	3.9	488
83	Amyloid Associated Proteins in Alzheimers and Prion Disease. <i>CNS and Neurological Disorders</i> , 2005, 4, 235-248.	4.3	55
84	C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. <i>Neurobiology of Disease</i> , 2005, 19, 10-17.	2.1	91
85	Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. <i>Neurobiology of Disease</i> , 2005, 19, 273-282.	2.1	21
86	Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2005, 2, 27.	3.1	44
87	C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. <i>European Journal of Clinical Investigation</i> , 2004, 34, 803-810.	1.7	27
88	How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. <i>Aging Cell</i> , 2004, 3, 169-176.	3.0	319
89	Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. <i>Neurobiology of Disease</i> , 2004, 15, 492-499.	2.1	57
90	Microglia kill amyloid- $\beta$ 1-42 damaged neurons by a CD14-dependent process. <i>NeuroReport</i> , 2004, 15, 1427-1430.	0.6	37

#	ARTICLE	IF	CITATIONS
91	Amyloid $\beta$ plaque-associated proteins C1q and SAP enhance the A $\beta$ 42 peptide-induced cytokine secretion by adult human microglia in vitro. <i>Acta Neuropathologica</i> , 2003, 105, 135-144.	3.9	129
92	Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2003, 110, 949-955.	1.4	163
93	Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer's Disease. <i>Current Drug Targets</i> , 2003, 4, 461-468.	1.0	75
94	Cyclin D1 and Cyclin E Are Co-Localized with Cyclo-Oxygenase 2 (COX-2) in Pyramidal Neurons in Alzheimer Disease Temporal Cortex. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 678-688.	0.9	102
95	Adult human microglia secrete cytokines when exposed to neurotoxic prion protein peptide: no intermediary role for prostaglandin E2. <i>Brain Research</i> , 2002, 925, 195-203.	1.1	30
96	Neuroinflammation in Alzheimer's disease and prion disease. <i>Glia</i> , 2002, 40, 232-239.	2.5	393
97	CSF markers related to pathogenetic mechanisms in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2002, 109, 1491-1498.	1.4	32
98	Immunological Aspects of Alzheimer's Disease. <i>BioDrugs</i> , 2001, 15, 325-337.	2.2	18
99	Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. <i>Acta Neuropathologica</i> , 2001, 101, 2-8.	3.9	229
100	Establishment of microglial cell cultures derived from postmortem human adult brain tissue: Immunophenotypical and functional characterization. <i>Microscopy Research and Technique</i> , 2001, 54, 34-39.	1.2	38
101	Interleukin-1 $\beta$ induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. <i>Experimental Gerontology</i> , 2001, 36, 559-570.	1.2	72
102	Costimulatory Effects of Interferon- $\gamma$ and Interleukin-1 $\beta$ or Tumor Necrosis Factor $\alpha$ on the Synthesis of A $\beta$ 1-40 and A $\beta$ 1-42 by Human Astrocytes. <i>Neurobiology of Disease</i> , 2000, 7, 682-689.	2.1	227
103	Inflammation and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2000, 21, 383-421.	1.5	4,069
104	Isolation and characterization of adult microglial cells and oligodendrocytes derived from postmortem human brain tissue. <i>Brain Research Protocols</i> , 2000, 5, 85-94.	1.7	73
105	Cytokines Associated with Amyloid Plaques in Alzheimer's Disease Brain Stimulate Human Glial and Neuronal Cell Cultures to Secrete Early Complement Proteins, But Not C1-Inhibitor. <i>Experimental Neurology</i> , 1999, 160, 289-299.	2.0	140
106	Complement C1-inhibitor expression in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1998, 96, 287-296.	3.9	60
107	Distribution of A $\beta$ -associated proteins in cerebrovascular amyloid of Alzheimer's disease. <i>Acta Neuropathologica</i> , 1998, 96, 628-636.	3.9	61
108	NSAIDs inhibit the IL-1 $\beta$ -induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. <i>Brain Research</i> , 1997, 777, 210-218.	1.1	78

#	ARTICLE	IF	CITATIONS
109	The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 1996, 17, 673-680.	1.5	194
110	Early complement components in Alzheimer's disease brains. <i>Acta Neuropathologica</i> , 1995, 91, 53-60.	3.9	68
111	Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1995, 426, 603-610.	1.4	60
112	Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. <i>Experimental Neurology</i> , 1995, 4, 291-297.	1.7	62
113	Role of Inflammation and Complement Activation in Alzheimer's Disease. , 1995, , 171-193.		2